| Document |
Document Title |
|
WO/2022/162693A1 |
The present invention relates to a class of benzodiazepine compounds and a process for preparation thereof. The 1,5-benzodiazepine compounds effectively 5 function on targeted enzymes such as tyrosine kinase and dihydrofolate reductase (...
|
|
WO/2022/133551A1 |
The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for ...
|
|
WO/2015/136557A9 |
The present invention provides compounds of formula (I), compositions, uses thereof and methods for inhibiting proliferation or obliterating cancer stem cells which includes killing; and/or inducing apoptosis in cancer stem cells. Includ...
|
|
WO/2022/105542A1 |
Disclosed are a deuterated 1,4-benzodiazepine-2,5-dione compound and the use thereof. Provided is a compound as represented by formula I or a pharmaceutically acceptable salt thereof. The disclosed 1,4-benzodiazepine-2,5-dione active com...
|
|
WO/2022/099011A1 |
Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is...
|
|
WO/2022/082305A1 |
The present disclosure provides compounds that are amylin receptor antagonist compounds, compositions that include the subject compounds, methods for preparing and using the amylin receptor antagonists, and compositions containing the am...
|
|
WO/2022/086892A1 |
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
|
|
WO/2022/034616A1 |
Described herein is a method for treating and/or preventing a disease or disorder or condition associated with NETosis, the method comprising: administering to a subject a compound as disclosed herein, or its polymorph, stereoisomer, pro...
|
|
WO/2022/022846A1 |
The present invention relates to a compound of general formula (I) wherein R1-7, Hy, and X are as defined in claim 1. Such compound of formula (I) binds to VDAC1 and is suitable for use in a method for treating diabetes or pre- diabetes ...
|
|
WO/2022/000443A1 |
Provided herein are compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.
|
|
WO/2021/249463A1 |
The present invention relates to a compound as represented by formula (I). Also provided are a composition and a preparation containing the compound, and a method for using and preparing the compound.
|
|
WO/2021/237111A1 |
Disclosed herein, inter alia, are compounds for inhibiting Notch and uses thereof.
|
|
WO/2021/237112A1 |
Disclosed herein, inter alia, are compounds for inhibiting Notch and uses thereof.
|
|
WO/2021/226629A1 |
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses o...
|
|
WO/2021/218863A1 |
The present invention relates to the field of chemical medicine, and in particular, to a 1,5-dihydro-2,4-benzodiazepine-3-one derivative and an application thereof. The 1,5-dihydro-2,4-benzodiazepine-3-one derivative provided by the pres...
|
|
WO/2021/208945A1 |
Disclosed are a benzonitric heterocyclic compound, a preparation method therefor and the use thereof. Provided in the present invention is a benzonitric heterocyclic compound represented by formula I, or a pharmaceutically acceptable sal...
|
|
WO/2021/208918A1 |
Provided are a class of compounds, represented by formula (I"'), as selective EGFR inhibitors, a pharmaceutical composition containing the compounds, useful intermediates for preparing the compounds, and a method for using the compounds ...
|
|
WO/2021/188620A1 |
Peptidomimetic N5-methyl-N2-(nonanoyl-L-leucyl)-L-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds for use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sa...
|
|
WO/2021/169963A1 |
Provided are a compound containing an aromatic group as well as a stereoisomer, a tautomer or a pharmaceutically acceptable salt of the compound. Further provided is a method related to preparation and use of the compound. A pharmaceutic...
|
|
WO/2021/170913A1 |
Chemical modulators of PP2A, comprising tricyclic sulfonimidamides are disclosed. The compounds are useful in preventing or treating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic o...
|
|
WO/2021/163676A1 |
The present invention provides methods of preparing compound of Formula (I), wherein the compounds are represented by the structure of Formula (I) wherein: R1 each is independently F, Cl, Br, I, OCH3, CN or NO2; R2 each is independently ...
|
|
WO/2021/141969A1 |
Lipid nanoparticle compositions for delivery of nucleic acids are described. In various embodiments the lipid nanoparticle contains an ionizable lipid of the Formula (I). Methods of using such lipid nanoparticle compositions to achieve t...
|
|
WO/2021/018298A1 |
Disclosed is a class of indolo-seven-membered acyloxime compounds, and specifically disclosed are compounds as shown in formula (I), and pharmaceutically acceptable salts thereof.
|
|
WO/2020/245213A1 |
The present invention relates to tricyclic derivatives of formula (I), which are useful as inhibitors of HECT-domain-containing E3 ligases, in particular NEDD4. The present invention also refers to pharmaceutical compositions comprising ...
|
|
WO/2020/242923A1 |
This disclosure relates to uses of radiation and benzodiazepines optionally in combination with other anticancer agents for treating cancer. In certain embodiments, this disclosure relates to methods of using radiation, benzodiazepines, ...
|
|
WO/2020/210662A1 |
The present disclosure provides compounds of formula (I), as described herein, their pharmaceutically acceptable salts, and their pharmaceutical compositions, which are effective in reducing the expression level of KLF5 or EGR1 in a livi...
|
|
WO/2020/200283A1 |
In an embodiment of the present invention, a fluorenone ligand compound for an α7 nicotinic acetylcholine receptor represented by the following formula (I) is provided, wherein, X is a 6- to 10-membered nitrogen-containing heterocyclic ...
|
|
WO/2020/192637A1 |
Disclosed are a solid form and a crystal form of a compound represented by formula (1) used as a BRD4 inhibitor, a preparation method therefor, and an application thereof in the preparation of a medicine for treating BRD4-related disease...
|
|
WO/2020/184670A1 |
The present invention relates to a method for monodeuterated lower alkylating an amine moiety of a compound which contains an amine that is protected by an aralkyl group, wherein a monodeuterated lower alkyl is introduced into the amine ...
|
|
WO/2020/131000A1 |
The invention relates to a crystalline form of the Compound (I), wherein the crystalline form displays its strongest reflection, stated as a 2Θ value, at 25±0.2°, in an X-ray powder diffraction pattern. The invention also relates to a...
|
|
WO/2020/127390A1 |
A method is provided for preparing a compound d having the formula (D) The method comprises carrying out the following reaction (c) → (d), where the reaction is carried out at a temperature of at least 100 °C and in the presence of a ...
|
|
WO/2020/127385A1 |
A method is provided for preparing a compound d having the formula: Formula (I). The method comprises carrying out the following reaction: Formula (i), (ii), (d) where: step (i) is carried out in the presence of a metal catalyst and a hy...
|
|
WO/2020/039631A1 |
Disclosed is a compound represented by formula (1): Q-CHR2 (1) (in the formula, Q represents a nitrogen-containing aliphatic group that includes two or more tertiary nitrogen atoms, and does not include oxygen, and R represents an alipha...
|
|
WO/2020/035464A1 |
The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 and R3 are each independently hydrogen or an optionally substituted hydrocarbyl group, or R1 and R3 together with the nitrogen atom to which...
|
|
WO/2020/027304A1 |
Provided are carotenoid derivatives having exceptional hydrophilicity and oral absorptivity. A carotenoid-related compound represented by the formula (in the formula, X represents a carbonyl group or a methylene group, and Z1 and Z2 are ...
|
|
WO/2020/021021A1 |
The present invention relates to ortho substituted phenoxypropylamino and benzyloxypropylamino derivatives having pharmacological activity towards the α2δ subunit of the voltage-gated calcium channel, in particular to ortho substituted...
|
|
WO/2020/011086A1 |
Involved are a class of benzodiazepine heterocyclic compounds, a preparation method therefor and the use thereof, as well as a pharmaceutical composition containing the compound. In particular, the present invention relates to the compou...
|
|
WO/2019/246541A1 |
The application relates to compounds, or pharmaceutically acceptable salts, hydrates, solvates, or stereoisomers thereof, which modulate the activity of EGFR, a pharmaceutical composition comprising said compounds, and methods of treatin...
|
|
WO/2019/245047A1 |
The purpose of the present invention is to provide a technique for imaging the brain of a living animal and application of the technique. A radiolabeled dibenzoazepine derivative, which shows excellent brain transferability, high recepto...
|
|
WO/2019/222298A1 |
The present invention provides methods of use for compositions comprising bisfluoroalkyl-l,4-benzodiazepinone compounds, including compounds of Formula (I) or prodmgs thereof; for treating diseases and disorders such as cancer.
|
|
WO/2019/168688A9 |
The present invention includes a solid lyophilized form of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-
benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (Compound I) and the process of producing the ...
|
|
WO/2019/215427A1 |
A process for forming a carbon-carbon bond to couple an aryl or heteroaryl group of a first compound with an alkyl or cycloalkyl moietyof a second compound, the process comprising reacting the first compound with the second compound in t...
|
|
WO/2019/173327A1 |
Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II).
|
|
WO/2019/164947A1 |
The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method o...
|
|
WO/2019/164948A1 |
The application relates to a compound having Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, ...
|
|
WO/2019/120212A1 |
Disclosed in the present invention is a new class of compounds that act as indoleamine-pyrrole 2,3-dioxygenase (IDO) inhibitors, and specifically disclosed thereby are a compound represented by formula (I) and a pharmaceutically acceptab...
|
|
WO/2019/115429A1 |
The invention relates to compounds according to the general formula (I) or a pharmaceutically acceptable salt of an inorganic or organic acid, a hydrate, a stereoisomer or a solvate thereof, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 a...
|
|
WO/2019/103658A2 |
The invention relates to novel compounds that are derivatives of 1,4-benzodiazapin-2-one, having the general formula (I) and being limited to structural variants (1-6), on the condition that: а) structures 1 (R1=Br, R4=F), 3 (R1=OCF3, R...
|
|
WO/2019/099560A1 |
The present subject matter provides compositions, formulations and methods for preventing or reducing proliferation or migration of retinal cells or epithelial to mesenchymal transition in ocular cells or cells from other tissues.
|
|
WO/2019/094903A1 |
The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors. The present invention also relates to p...
|
